Human Embryonic Stem Cell Clinical Trials[edit] Introduction[edit]
The Food and Drug Administration (FDA) approved the first clinical trial in the United States involving human embryonic stem cells on January 23, 2009. Geron Corporation, a biotechnology firm located in Menlo Park, California, originally planned to enroll ten patients suffering from spinal cord injuries to participate in the trial. The company hoped that GRNOPC1, a product derived from human embryonic stem cells, would stimulate nerve growth in patients with debilitating damage to the spinal cord.[1] The trial began in 2010 after being delayed by the FDA because cysts were found on mice injected with these cells, and safety concerns were raised.[2]
In the United States, the FDA must approve all clinical trials involving newly developed pharmaceuticals. Researchers must complete an Investigational New Drug (IND) application in order to earn the FDAs approval. IND applications typically include data from animal and toxicology studies in which the drugs safety is tested, drug manufacturing information explaining how and where the drug will be produced, and a detailed research protocol stating who will be included in the study, how the drug will be administered and how participants will be consented.[3] Testing for new drugs must successfully go through three phases of research before a drug can be marketed to the public. In Phase I trials, the drugs safety is tested on a small group of participants. The drugs effectiveness is tested during Phase II trials with a larger number of participants. Phase III trials, involving 1,000- 3,000 participants, analyze effectiveness, determine side effects and compare the outcomes of the new drug to similar drugs on the market.[4] An additional phase, Phase IV, is included to continually gain information after a drug is on the market. Gerons IND application for the GRNOPC1 clinical trial, nearly 28,000 pages in length, was one of the most extensive applications ever to be submitted to the FDA.[2]
Before Geron could test GRNOPC1 in humans, tests in animals had to occur. At the University of California at Irvine, Dr. Hans Keirstead and Dr. Gabriel Nistor, credited with the technique used to develop oligodendrocytes from human embryonic stem cells, injected the cells into rats with spinal cord injuries. The condition of the rats improved after treatment.[5]
The first patient, identified in an article by the Washington Post as Timothy J. Atchison of Alabama, enrolled in the trial in October 2010. The patient was treated at the Shepherd Center in Atlanta, GA just two weeks after he sustained a spinal cord injury in a car accident. The Shepherd Center and six other spinal centers were recruited by Geron to participate in the clinical trial. The Washington Post reported that Atchison has begun to get some very slight sensation: He can feel relief when he lifts a bowling ball off his lap and discern discomfort when he pulls on hairs on some parts of his legs. He has also strengthened his abdomen. Atchison underwent therapy at the Shepherd Center for three months before returning home to Alabama.[6]
Although Geron initially aimed to enroll ten patients in the trial, only three additional patients were added after Atchison. As specified by Geron, eligible patients had to experience a neurologically complete spinal cord injury within seven to fourteen days prior to enrollment. In addition, patients had to be between the ages of 18 and 65 and could not have a history of malignancy, significant organ damage, be pregnant or nursing, unable to communicate or participate in any other experimental procedures. Participants received one injection of GRNOPC1 containing approximately 2 million cells. Even though the trial has officially ended, Geron will continue to monitor participants for fifteen years.[7]
Although no official results from the trial have been published, preliminary results from the clinical trial were presented at the American Congress of Rehabilitation Medicine (ACRM) conference in October 2011. None of the participants experienced serious adverse events, although nausea and low magnesium were reported. In addition, no changes to the spinal cord or neurological condition were found.[8]
After investing millions of dollars in the research leading up to this trial, Geron Corporation discontinued the study in November 2011 to focus on cancer research. John Scarlett, Gerons chief executive officer, said In the current environment of capital scarcity and uncertain economic conditions, we intend to focus our resources on advancing our two novel and promising oncology drug candidates.[9] The companys stocks fell dramatically to $1.50 per share from $2.28 per share when news of the trials discontinuation became public. A spokesperson for the company said that Geron would save money by ending the trial despite the loss in investors. Because many believed Gerons trial offered hope for advancing knowledge related to stem cells and their potential uses, there was disappointment in the scientific community when the trial was cut short. An article on Bioethics Forum, a publication produced by The Hastings Center, stated, "It is one thing to close a trial to further enrollment for scientific reasons, such as a problem with trial design, or for ethical reasons, such as an unanticipated serious risk of harm to participants. It is quite another matter to close a trial for business reasons, such as to improve profit margins."[10]
In 2013 Geron's stem cell assets were acquired by biotechnology firm BioTime, helmed by CEO Michael D. West, the founder of Geron and former Chief Scientific Officer of Advanced Cell Technology. BioTime indicated that it plans to re-start the embryonic stem cell-based clinical trial for spinal cord injury.[11]
Two clinical trials involving derivatives of human embryonic stem cells were approved in 2010. Advanced Cell Technology (ACT) located in Marlborough, Massachusetts, leads the trials aimed at improving the vision of patients with Stargardts Macular Dystrophy and Dry Age-Related Macular Degeneration. Originally, twelve patients were estimated to enroll at three hospitals in the U.S.; participating institutions included the Casey Eye Institute in Portland, Oregon, University of Massachusetts Memorial Medical Center in Worchester, Massachusetts, and the New Jersey Medical School in Newark, New Jersey.[12] Patients eyes were injected with retinal pigmented epithelial cells derived from human embryonic stem cells. While no definitive findings from this study have been produced, an article published in Lancet in January 2012 stated that preliminary findings appear to be promising. In this article, outcomes from two patients treated as part of the trial were discussed. During the trial, neither patients vision worsened, and no negative side effects were reported.[13]
Read more from the original source:
Human embryonic stem cells clinical trials - Wikipedia ...
- Woman Who Conceived Twins in Rape Rejects Abortion, Shares How Her 21-Year-Old Twins Saved Her Life - The Epoch Times - October 13th, 2022
- Kid Captain Eli Belser takes the field with Hawkeyes, celebrating two years cancer free - UI The Daily Iowan - September 8th, 2022
- How space technology like the James Webb telescope is improving healthcare on Earth - The National - July 27th, 2022
- How COVID-19, Long COVID, and COVID Vaccines Differ Between Males and Females - CreakyJoints - July 27th, 2022
- Researchers find fabrication of artificial heart for transplant - ThePrint - July 19th, 2022
- Paolo Macchiarini - Wikipedia - July 3rd, 2022
- President Freeman Hrabowski prepares for retirement after turning UMBC into the top producer of Black M.D., Ph.D. graduates - Afro American - July 3rd, 2022
- Women find community in STEM fields at UA - The University of Alabama Crimson White - April 19th, 2022
- Poker Run event planned to benefit twins with rare syndrome - The Andalusia Star-News - Andalusia Star-News - April 6th, 2022
- Dr Borehams Crucible: Mesoblast within months of 3 major trial results, key regulatory decision - Stockhead - July 6th, 2020
- Alabama Stem Cells | Stem Cell TV - September 12th, 2019
- Only Cosmetic Stem Cell Therapy in Alabama - msbmd.com - April 20th, 2019
- Stem Cell Therapy in Houston, TX | National Stem Cell Centers - March 23rd, 2019
- Central Alabama Pain Management Center Established 1993 - March 6th, 2019
- Stem Cell Mobile Alabama 36607 - January 4th, 2019
- Stem Cell Birmingham Alabama 35282 - August 30th, 2018
- USA College of Medicine - University of South Alabama ... - July 24th, 2018
- Researchers find new glioblastoma inhibitor - Patient Daily - August 24th, 2017
- A Chip That Reprograms Cells Helps Healing, At Least In Mice - Alabama Public Radio - August 12th, 2017
- 'Happiness' Explores The Complex Push And Pull Of Human Relationships - Alabama Public Radio - August 12th, 2017
- Hampton Creek to enter clean meat market in 2018: 'We are building a multi-species, multi-product platform' - FoodNavigator-USA.com - June 30th, 2017
- Brain Tumors: Still Devastating, but Treatment Has Come a Long Way - Newswise (press release) - June 20th, 2017
- Walk for "terrible, awful" disease - Timmins Press - June 18th, 2017
- Rare disease hits 2 of family's 4 children - The Ledger - June 18th, 2017
- Hill-Rom Holdings, Inc. (HRC) Reaches $76.89 52-Week High, Biotime (NYSEMKT:BTX) Shorts Increased By 4.64% - UtahHerald.com - June 13th, 2017
- STEM College Students Who Learn by Example May Lack Key Attribute - GoodCall News (blog) - June 13th, 2017
- Wolf Evolution and Settled Science - PLoS Blogs (blog) - June 8th, 2017
- 3D-Printed Patch Mends Hearts - Photonics.com - June 6th, 2017
- When states have strong guns laws, they also have fewer fatal police shootings - Los Angeles Times - May 19th, 2017
- Top graduating senior in 'crazy race to the finish line' | Berkeley News - UC Berkeley - May 9th, 2017
- 3D-printed patch could lead to new treatments for patients after a heart attack - Biotechin.Asia - May 5th, 2017
- Meet Curry Cates: 2017 Big Man on Campus - The Auburn Plainsman - April 28th, 2017
- Andrews Institute Looks Ahead - Inweekly - April 27th, 2017
- UMN research team fixes broken hearts with 3D-printed tissue patch - Minnesota Daily - April 27th, 2017
- Bengals set to hold onto McCarron for at least 1 more year | Sports ... - Newsexaminer - April 27th, 2017
- Andrews Institute Celebrates Ten Years, Looks to Next Ten - WUWF - April 25th, 2017
- Scientists want to help you recover heart attack with a 3d printed patch - Industry Leaders Magazine - April 25th, 2017
- Bengals set to hold onto McCarron for at least 1 more year - WTOP - April 25th, 2017
- Mending broken hearts - The Sydney Morning Herald - April 22nd, 2017
- 3D-printed Patch Can Help Mend a 'Broken' Heart | Technology ... - Technology Networks - April 22nd, 2017
- UAB performs Alabama's first transplant where cadaver liver is 'kept ... - Medical Xpress - April 22nd, 2017
- Heart-healing patch has got the beat - New Atlas - April 20th, 2017
- 3D-printed Patch Can Help Mend a 'Broken' Heart - Technology Networks - April 19th, 2017
- 3D-Printed Patch Can Help Mend a 'Broken' Heart | Lab Manager - Lab Manager | News (press release) (blog) - April 18th, 2017
- 3D-printed patch can help mend a broken heart - UMN News - April 14th, 2017
- Bart Starr returns to Tijuana for stem cells - USA Today - April 10th, 2017
- Pioneering Investigators in Experimental Heart Stem Cell and ... - Newswise (press release) - April 9th, 2017
- The mystique of the invisible: Understanding mental illness - Glens Falls Post-Star - March 27th, 2017
- The Equities Research Analysts' Updated EPS Estimates for March, 20th (AIMT, AMID, AUPH, AVD, BDREF, BPTH ... - Petro Global News 24 - March 23rd, 2017
- Hettinger, ND gets state-of-art new clinic and vets - AG Week - March 21st, 2017
- Harvard Scientists Call For Better Rules To Guide Research On 'Embryoids' - Alabama Public Radio - March 21st, 2017
- State-of-art new clinic - and vets - The Dickinson Press - March 19th, 2017
- 3 Women Blinded By Unproven Stem Cell Treatments - Alabama Public Radio - March 16th, 2017
- Hot Biotech Stocks Recap: Nektar Therapeutics (NASDAQ:NKTR), Biostage, Inc. (NASDAQ:BSTG) - The Voice Registrar - March 7th, 2017
- Trump's coal council to drill down on advanced technology - Washington Examiner - March 6th, 2017
- Embryo Experiments Reveal Earliest Human Development, But Stir Ethical Debate - Alabama Public Radio - March 3rd, 2017
- Houston Solar Car featured in IMAX film, Smithsonian - Northeast Mississippi Daily Journal - February 24th, 2017
- News Scan for Feb 20, 2017 - CIDRAP - February 21st, 2017
- On Second Attempt, SpaceX Launches Rocket At NASA's Historic Pad - Alabama Public Radio - February 20th, 2017
- A Liftoff Deferred: SpaceX Mission From NASA's Historic Launch Pad Delayed - Alabama Public Radio - February 19th, 2017
- ECO VIEWS: Advertising is not just for humans - Tuscaloosa News - February 13th, 2017
- ECOViEWS: Advertising is not just for humans - Aiken Standard - February 11th, 2017
- Unsung: Jewel Plummer Cobb - Undark Magazine - February 8th, 2017
- Bart Starr prepares to watch Super Bowl from home as health keeps improving - USA TODAY - February 7th, 2017
- Romero '87 Sees ACLU Donations Soar, Munson *79 to Lead RIT, and More - Princeton Alumni Weekly - February 7th, 2017
- Meet the Team - The University of Alabama at Birmingham - January 26th, 2017
- Tallasee Dog Undergoes Stem Cell Procedure - Alabama News - December 30th, 2016
- Dermal fibroblast - Wikipedia - November 27th, 2016
- Stem Cell Hair Growth Huntsville | Steve Latham Hair ... - September 12th, 2016
- Adult Stem Cell Success - Children of God for Life - April 18th, 2015
- Can cancer vaccines prolong survival? - April 7th, 2015
- Christian singer Carman shares testimony of cancer victory - February 2nd, 2015
- Urban Dictionary: stem cell - January 21st, 2015
- Huntsville blood bank to preserve umbilical cord tissues - November 25th, 2014
- CGS : 60 Minutes Exposes Stem Cell Scams Again - November 22nd, 2014
- What Are Stem Cells? (with pictures) - wiseGEEK - November 16th, 2014
- alabama StemCells Therapy StemCells Therapy - October 24th, 2014
- Life Issues Institute - Successes of Adult Stem Cell ... - October 16th, 2014
- A heartbeat away? Hybrid 'patch' could replace transplants - October 1st, 2014
- Huntsville AL Resources - Stem Cells: Get Facts on Uses ... - September 29th, 2014